EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant RAS Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize Treatment

JCO Precision Oncology - United States
doi 10.1200/po.17.00277
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-Egfr Therapy and Molecularly Selected by Circulating Tumor DNA Analyses

JAMA Oncology
Cancer ResearchOncology
2018English

Early Change in Circulating Tumor DNA as a Potential Predictor of Response to Chemotherapy in Patients With Metastatic Colorectal Cancer

Scientific Reports
Multidisciplinary
2019English

Change in Circulating Tumor DNA After Hepatic Resection for Metastatic Colorectal Cancer

HPB
HepatologyGastroenterology
2018English

Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation

OncoTargets and Therapy
OncologyPharmacology
2013English

Dermatologic Toxicity Occurring During Anti-Egfr Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer

Frontiers in Genetics
GeneticsMolecular Medicine
2019English

Xeloda as First-Line Therapy of Metastatic Colorectal Cancer-Our Experience

Archive of Oncology
OncologyHematology
2002English

Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

Farmeconomia. Health economics and therapeutic pathways
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy